Unknown

Dataset Information

0

Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.


ABSTRACT: The GH/IGF1 response of somatotropinomas to somatostatin analogues (SSA) is associated with their pattern of somatostatin receptor (sst1-sst5) expression. Recently, we demonstrated that expression of a truncated sst5-variant (sst5TMD4) can influence the secretory response of somatotropinomas to SSA-therapy; however, its potential relationship with aggressive features (e.g. invasion/proliferation) is still unknown. Here, we show that sst5TMD4 is present in 50% of non-functioning pituitary-adenomas (NFPA) (n?=?30) and 89% of somatotropinomas (n?=?36), its expression levels being highest in somatotropinomas?>?>?NFPAs?>?>?>?normal pituitaries (negligible expression; n?=?8). In somatotropinomas, sst5TMD4 mRNA and protein levels correlated positively, and its expression was directly associated with tumor invasiveness (cavernous/sphenoid sinus), and inversely correlated with age and GH/IGF1 reduction after 3-6?months with octreotide-LAR therapy. GNAS+ somatotropinomas expressed lower sst5TMD4 levels. ROC analysis revealed sst5TMD4 expression as the only marker, within all sst-subtypes, capable to predict tumor invasiveness in somatotropinomas. sst5TMD4 overexpression increased cell viability in cultured somatotropinoma (n?=?5). Hence, presence of sst5TMD4 associates with increased aggressive features and worse prognosis in somatotropinomas, thereby providing a potentially useful tool to refine somatotropinoma diagnosis, predict outcome of clinical response to SSA-therapy and develop new therapeutic targets.

SUBMITTER: Luque RM 

PROVIDER: S-EPMC4378269 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications


The GH/IGF1 response of somatotropinomas to somatostatin analogues (SSA) is associated with their pattern of somatostatin receptor (sst1-sst5) expression. Recently, we demonstrated that expression of a truncated sst5-variant (sst5TMD4) can influence the secretory response of somatotropinomas to SSA-therapy; however, its potential relationship with aggressive features (e.g. invasion/proliferation) is still unknown. Here, we show that sst5TMD4 is present in 50% of non-functioning pituitary-adenoma  ...[more]

Similar Datasets

| S-EPMC4872735 | biostudies-literature
| S-EPMC2730344 | biostudies-literature
| S-EPMC3485222 | biostudies-literature
| EMPIAR-10932 | biostudies-other
| S-EPMC7069942 | biostudies-literature
| S-EPMC3070569 | biostudies-literature
| S-EPMC4649711 | biostudies-literature
| S-EPMC7470473 | biostudies-literature
| S-EPMC5844672 | biostudies-literature
| S-EPMC5324734 | biostudies-literature